Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
High-titer COVID-19 convalescent plasma
- Development stage
- Unknown
- Lead developer
- University of North Carolina at Chapel Hill
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
High-titer COVID-19 convalescent plasma (CCP1) is a biologic therapy consisting of plasma derived from individuals who have recovered from SARS-CoV-2 infection, specifically selected for having high levels of neutralizing antibodies. Developed and studied by the University of North Carolina at Chapel Hill in the Phase 2 CoVIP trial (NCT04524507), this therapy aims to provide passive immunity to hospitalized COVID-19 patients. The neutralizing antibodies within the plasma bind to the SARS-CoV-2 spike protein, preventing viral entry into host cells and thereby reducing viral load and disease progression. The UNC study specifically investigated whether high-titer plasma offers superior clinical outcomes compared to standard-titer plasma in patients with early-stage hospitalization.
- Other names
- High-titer Convalescent COVID-19 PlasmaCOVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmaCCPCCP1-University of North Carolina, Chapel Hill-COVID-19
02
Targets
BVDV E2 (Bovine viral diarrhea virus glycoprotein E2)RBD (SARS-CoV-2 spike receptor-binding domain)N (Nucleocapsid protein)
Beyond the preview
Go deeper on High-titer COVID-19 convalescent plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on High-titer COVID-19 convalescent plasma.